Q1 Earnings Forecast for Compugen Issued By HC Wainwright

Compugen Ltd. (NASDAQ:CGEN) – Analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Compugen in a research report issued on Tuesday, May 19th. HC Wainwright analyst S. Ramakanth anticipates that the biotechnology company will post earnings per share of ($0.10) for the quarter. The consensus estimate for Compugen’s current full-year earnings is ($0.26) per share. HC Wainwright also issued estimates for Compugen’s Q2 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.11) EPS, Q4 2027 earnings at ($0.11) EPS, FY2028 earnings at ($0.44) EPS, FY2029 earnings at ($0.45) EPS and FY2030 earnings at ($0.30) EPS.

Other research analysts have also issued reports about the stock. Lake Street Capital initiated coverage on shares of Compugen in a report on Tuesday, April 7th. They issued a “buy” rating and a $6.00 price objective for the company. Truist Financial upgraded shares of Compugen to a “strong-buy” rating in a research report on Wednesday, March 25th. Wall Street Zen raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $5.00.

Compugen Stock Down 4.4%

NASDAQ:CGEN opened at $2.73 on Wednesday. The firm’s fifty day simple moving average is $2.52 and its 200 day simple moving average is $2.00. The stock has a market cap of $258.50 million, a P/E ratio of 7.39 and a beta of 2.79. Compugen has a twelve month low of $1.29 and a twelve month high of $3.23.

Compugen (NASDAQ:CGEN) last announced its earnings results on Monday, May 18th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Compugen had a net margin of 47.97% and a return on equity of 53.13%. The business had revenue of $2.18 million for the quarter, compared to the consensus estimate of $1.57 million.

Institutional Investors Weigh In On Compugen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Platform Technology Partners increased its stake in shares of Compugen by 10.0% during the first quarter. Platform Technology Partners now owns 55,000 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 5,000 shares in the last quarter. State Street Corp grew its stake in shares of Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after buying an additional 14,701 shares during the last quarter. Two Sigma Investments LP increased its position in Compugen by 10.6% during the 3rd quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 18,929 shares in the last quarter. Bank Hapoalim BM bought a new position in Compugen during the 4th quarter valued at approximately $37,000. Finally, Security National Bank of Sioux City Iowa IA purchased a new position in Compugen during the fourth quarter valued at $38,000. Hedge funds and other institutional investors own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.